Dabur gets US FDA warning for Silvassa unit; says impact is limited to private-label exports
The US FDA flagged data-integrity and maintenance gaps at part of Dabur’s Silvassa facility and placed it under Import Alert 66-40. Dabur says domestic operations and branded products are unaffected, revenue exposure is immaterial, and remediation plus alternate US sourcing are underway.
Dabur received a US FDA warning over data-integrity and maintenance gaps at part of its Silvassa plant serving private-label exports. It says domestic products and operations are unaffected, the revenue impact is immaterial, and remediation and alternate US sourcing are underway.
Why this matters
The FDA action adds a compliance issue as Dabur targets double-digit FY27 revenue growth and contests FSSAI’s ban on “100%” claims for honey and ghee in Delhi High Court.
Retail-company signals are accelerating, up 95,100% QoQ.